LENZ Therapeutics (LENZ) Depreciation & Amortization (CF) (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Depreciation & Amortization (CF) of $111000.0 for Q1 2026, up 208.33% year-over-year from $36000.0 in Q1 2025, and up 3.74% quarter-over-quarter from $107000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $111000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 208.33% year-over-year to $111000.0; the TTM figure through Mar 2026 stood at $362000.0 (up 306.74% YoY), while the FY2025 annual figure was $287000.0, up 394.83% from the prior year.
- Depreciation & Amortization (CF) rose to $111000.0 in Q1 2026 per LENZ's latest filing, from $107000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $682000.0 in Q4 2022 and bottomed at $3000.0 in Q1 2023.
- Historically, Depreciation & Amortization (CF) has averaged $166058.8 across 5 years, with a median of $25000.0 in 2024.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) slumped 99.41% — and 2025, when it surged 1150.0%.
- LENZ Therapeutics' Depreciation & Amortization (CF) stood at $682000.0 in 2022, then plunged by 99.41% to $4000.0 in 2023, then jumped by 525.0% to $25000.0 in 2024, then soared by 328.0% to $107000.0 in 2025, then grew by 3.74% to $111000.0 in 2026.
- Business Quant data shows LENZ's Depreciation & Amortization (CF) at $111000.0 in Q1 2026, $107000.0 in Q4 2025, and $125000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 110,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110,000.00 |
| Jun 30, 2026 | 110,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |